


Corporate Overview

REGENIX BIOSCIENCES

www.regenixbiosciences.in





About Us



Regenix Biosciences is a Chennai-based biopharmaceutical company dedicated to the development and manufacturing of high-quality biosimilar products.

Founded with a vision to make biologics affordable and accessible, we specialize in insulin biosimilars with robust R&D, GMP-compliant manufacturing, and global regulatory capabilities.

Our Mission

At Regenix Biosciences, our mission is to develop high-quality, affordable biosimilars that empower better healthcare outcomes.





Our Core Values

1

Integrity

Highest ethical standards in every decision and action

2

Innovation

Progress through scientific excellence and continuous improvement

3

Affordability

Committed to making quality biologics accessible to all

Our Leadership



Dr. Ramamurthy

Chairman & Managing Director



Dr. Balaji Ramamurthy

Executive Director



Mr. Viswanathan

Executive Director



Mr. Sethu Narayanan

Director



PRODUCT PORTFOLIO



Human Insulin Regular

Short Acting Insulin





Isophane Insulin NPH

Intermediate Acting Insulin





Bi-phasic Isophane Insulin 30/70

Pre-mix Insulin

- 30% Regular (short-acting) insulin
- 70% NPH (intermediate-acting) insulin





Insulin Glargine


Long Acting Insulin





Liraglutide


GLP - 1 Analogue





Enoxaparin

Low Molecular Weight Heparin



Product Status

Molecule	Delivery Device	Clinical trial Status	Development Status	Indication
Human Insulin regular	10ml Vial, 3ml Cartridge, 3ml Disposable Pen	Phase 1 & Phase 3 Completed	Final Marketing Authorization	Type I & II Diabetes Mellitus
Isophane Insulin NPH	10ml Vial, 3ml Cartridge, 3ml Disposable Pen	Phase I Completed	Exports Only	Type I & II Diabetes Mellitus
Bi-phasic Isophane Insulin 30/70	10ml Vial, 3ml Cartridge, 3ml Disposable Pen	Phase 1 & Phase 3 Completed	Final Marketing Authorization	Type I & II Diabetes Mellitus
Insulin Glargine	10ml Vial, 3ml Cartridge, 3ml Disposable Pen	Phase 1 & Phase 3 Completed	Approved	Type I & II Diabetes Mellitus

Product Status

Molecule	Delivery Device	Clinical trial Status	Development Status	Indication
Liraglutide	3ml Disposable Pen	Phase 1 & Phase 3 Completed	Final Marketing Authorization	Type 2 Diabetes Mellitus
Enoxaparin	40mg pfs, 60mg pfs, 300mg Cartridge, 300mg Disposable Pen	No Clinical Trials Conducted	Approved	Anticoagulant
Insulin Aspart	10ml Vial, 3ml Cartridge, 3ml Disposable Pen	Pipeline Product	API Sourcing	Type I & II Diabetes Mellitus
Semaglutide	3ml Disposable Pen	Pipeline Product	API Sourcing	Type 2 Diabetes Mellitus

Regenix
Manufacturing Facility

Regenix – cGMP Facility

» 30,000 sq. ft. GMP-certified

A modern 30,000 sq. ft. facility designed to meet global GMP compliance standards

» Formulation capacity: 50L × 3 vessels

Flexible formulation setup with three 50-liter vessels optimized for biologics

» Combi filling line

High-speed combi line supports vial, cartridge, and prefilled syringe formats at 3600 units/hour

» Built for clinical & semi-commercial scale

Purpose-built to handle PV, clinical trial, and semi-commercial production seamlessly

Our Core Departments



Production



Quality Assurance



Engineering



Quality Control



Delivery Devices



10ml Vial



3ml Disposable Pen



3ml Cartridge



1ml Pfs



Manufacturing Capacities

10ml Vial

600,000

1ml PFS

30,000,00

3ml Cartridge

20,000,00



Certifications

FORM 28

License to manufacture pharmaceutical products for sale or distribution under the Drugs and Cosmetics Act

FORM 28D


License to manufacture investigational new drugs (INDs) or drugs for clinical trials and examination

WHO-GMP

Certification of compliance with World Health Organization Good Manufacturing Practices for pharmaceutical quality and safety

PRODUCT DEVELOPMENT TIMELINES

(Total estimated period 2 year 7 months)



GLOBAL EXPORTS

- 1 Thailand
- 2 Philippines
- 3 Indonesia
- 4 Myanmar
- 5 Cambodia
- 6 Iraq
- 7 Nigeria
- 8 Peru
- 9 Chile
- 10 Guatemala

